Who Paid My Doc
Peter Karachunski
Child & Adolescent Psychiatry Minneapolis, MN Medical Doctor
NPI 1720176308 CMS profile 412320
2450 Riverside Ave Se, Minneapolis, MN 55455
General payments
$21,649
Research payments
$1,400
Ownership & investment interest
$0
Research they led as principal investigator
$618,924
Through program year 2024, Peter Karachunski of Minneapolis, MN is reported in the CMS Open Payments database as having received $21,649 across 35 general payments and $1,400 in research payments paid to them. Separately, studies naming them as principal investigator received $618,924 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $12,429 | 13 | |
| 2022 | General | $283 | 3 | |
| 2021 | General | $184 | 3 | |
| 2020 | General | $1,440 | 1 | |
| 2020 | Research | $1,400 | 1 | |
| 2019 | General | $7,313 | 15 |
Beside peers
- Peter Karachunski
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Peter Karachunski were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Peter Karachunski | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,313 | $129 | $42–$419 | $163 |
| 2020 | $1,440 | $81 | $28–$226 | $114 |
| 2021 | $184 | $115 | $31–$326 | $132 |
| 2022 | $283 | $124 | $40–$382 | $149 |
| 2023 | $0 | $130 | $45–$420 | $160 |
| 2024 | $12,429 | $141 | $42–$490 | $164 |
| 2025 | $0 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
443
Drug cost
$2,884,245
Branded share of claims
36.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Evrysdi Risdiplam | Brand | 90 | $2,566,169 | |
| Keveyis Dichlorphenamide | Brand | 11 | $243,912 | |
| Nayzilam Midazolam | Brand | 23 | $34,720 | |
| Briviact Brivaracetam | Brand | 13 | $17,979 | |
| Pyridostigmine Bromide | Generic | 42 | $5,908 | |
| Mexiletine Hcl | Generic | 24 | $3,660 | |
| Azathioprine | Generic | 28 | $2,538 | |
| Lisdexamfetamine Dimesylate | Generic | 11 | $2,225 | |
| Acetazolamide | Generic | 17 | $2,045 | |
| Mycophenolate Mofetil | Generic | 15 | $1,972 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$9,940
Medicare patients
72
Services billed
201
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 47% | |
| Arthritis | 29% | |
| Depression | 25% | |
| Diabetes | 19% | |
| Osteoporosis | 19% | |
| Atrial fibrillation | 18% | |
| Ischemic heart disease | 17% | |
| COPD | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
36 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Minnesota
Kim Holtmeier
Child & Adolescent Psychiatry · Golden Valley, MN
Israel Sokeye
Child & Adolescent Psychiatry · Plymouth, MN
Sreelatha Spieker
Child & Adolescent Psychiatry · Mankato, MN
Carl Hansen
Child & Adolescent Psychiatry · St Louis Park, MN
Travis Hansen
Child & Adolescent Psychiatry · Mankato, MN
Michael Adelman
Child & Adolescent Psychiatry · Baxter, MN
Related records
Child & Adolescent Psychiatry in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.